THE VALUE OF QUANTITATIVE MEASUREMENT OF HBEAG AND HBSAG BEFORE INTERFERON-ALPHA TREATMENT OF CHRONIC HEPATITIS-B IN CHILDREN

被引：18

作者：

BURCZYNSKA, B

MADALINSKI, K

PAWLOWSKA, J

WOYNAROWSKI, M

SOCHA, J

GERLICH, WH

WILLEMS, WR

WOZNIEWICZ, B

STACHOWSKI, J

机构：

[1] UNIV GIESSEN,INST MED VIROL,D-35392 GIESSEN,GERMANY

[2] CHILD HLTH CTR,DEPT CLIN IMMUNOL,WARSAW,POLAND

[3] CHILD HLTH CTR,DEPT GASTROL,WARSAW,POLAND

[4] CHILD HLTH CTR,DEPT PATHOMORPHOL,WARSAW,POLAND

[5] SECOND CLIN CHILDRENS DIS,POZNAN,POLAND

来源：

JOURNAL OF HEPATOLOGY | 1994年 / 21卷 / 06期

关键词：

HBV DNA; PREDNISONE TREATMENT; QUANTITATION OF HBSAG; TITER OF HBEAG;

D O I：

10.1016/S0168-8278(05)80624-5

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Serum concentrations of KBsAg, HBeAg and hepatitis B virus DNA were measured quantitatively before interferon treatment in 23 children (17 boys, 6 girls) suffering from chronic hepatitis B, and correlated to the outcome of the treatment. Five children remained HBsAg- and HBeAg-positive throughout the treatment and 6 months after the end of the treatment (non-responders), 12 children eliminated HBeAg but not HBsAg (partial responders) and six eliminated HBeAg and HBsAg (complete responders). The five non-responders had significantly higher initial HBsAg and HBeAg concentrations and significantly lower alanine aminotransferase levels than the partial or complete responders. The six complete responders had significantly lower HBsAg concentrations than the partial or non-responders, and seemed to be younger. No significant difference in HBV DNA levels was found in the three response groups. These data suggest that quantitative assays of HBsAg and HBeAg are particularly useful in selecting patients with chronic hepatitis B for interferon therapy. (C) Journal of Hepatology.

引用

页码：1097 / 1102

页数：6

共 26 条

[1] THE TREATMENT OF CHRONIC TYPE-B VIRAL-HEPATITIS [J].

AACH, RD .

ANNALS OF INTERNAL MEDICINE, 1988, 109 (02) :89-91

[2]

ANDERSON M G, 1985, Gut, V26, P848, DOI 10.1136/gut.26.8.848

[3] QUESTIONS OF QUALITY - HOW MUCH HBSAG IS THERE IN THIS SAMPLE AND IS OUR ASSAY SENSITIVE ENOUGH TO DETECT IT [J].

BARBARA, JAJ .

VOX SANGUINIS, 1993, 65 (04) :249-250

[4] FAILURE OF ACYCLOVIR TO ENHANCE THE ANTIVIRAL EFFECT OF ALPHA-LYMPHOBLASTOID INTERFERON ON HBE-SEROCONVERSION IN CHRONIC HEPATITIS-B - A MULTICENTER RANDOMIZED CONTROLLED TRIAL [J].

BERK, L ;

SCHALM, SW ;

DEMAN, RA ;

HEYTINK, RA ;

BERTHELOT, P ;

BRECHOT, C ;

BOBOC, B ;

DEGOS, F ;

MARCELLIN, P ;

BENHAMOU, JP ;

HESS, G ;

ROSSOL, S ;

ZUMBUSCHENFELDE, KHM ;

CHAMULEAU, RAFM ;

JANSEN, PLM ;

REESINK, HW ;

MEYER, B ;

BEGLINGER, C ;

STALDER, GA ;

DENOUDENMULLER, JW ;

DEJONG, M .

JOURNAL OF HEPATOLOGY, 1992, 14 (2-3) :305-309

[5] RANDOMIZED CONTROLLED TRIAL OF INTERFERON-ALFA-2A (RBE) (ROFERON-A) FOR THE TREATMENT OF CHRONIC HEPATITIS-B VIRUS (HBV) INFECTION - FACTORS THAT INFLUENCE RESPONSE [J].

BROOK, MG ;

MCDONALD, JA ;

KARAYIANNIS, P ;

CARUSO, L ;

FORSTER, G ;

HARRIS, JRW ;

THOMAS, HC .

GUT, 1989, 30 (08) :1116-1122

[6]

DIBISCEGLIE AM, 1990, HEPATOLOGY, V2, P266

[7] ADENINE-ARABINOSIDE MONOPHOSPHATE (VIDARABINE PHOSPHATE) IN COMBINATION WITH HUMAN-LEUKOCYTE INTERFERON IN THE TREATMENT OF CHRONIC HEPATITIS-B - A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL [J].

GARCIA, G ;

SMITH, CI ;

WEISSBERG, JI ;

EISENBERG, M ;

BISSETT, J ;

NAIR, PV ;

MASTRE, B ;

ROSNO, S ;

ROSKAMP, D ;

WATERMAN, K ;

POLLARD, RB ;

TONG, MJ ;

BROWN, BW ;

ROBINSON, WS ;

GREGORY, PB ;

MERIGAN, TC .

ANNALS OF INTERNAL MEDICINE, 1987, 107 (03) :278-285

[8]

GERLICH WH, 1973, DEV BIOL STAND, V30, P78

[9] THERAPY FOR HEPATITIS, WITH EMPHASIS ON THE ROLE OF INTERFERONS [J].

HANTZ, O ;

TURIN, F ;

TREPO, C .

CURRENT OPINION IN INFECTIOUS DISEASES, 1993, 6 (06) :778-783

[10]

HESS G, 1986, J HEPATOL, V3, P245

← 1 2 3 →